03.04.15
Johnson & Johnson sales for the fourth quarter of 2014 were almost flat at 0.6% down to $18.3 billion. Worldwide sales for the full-year rose 4.2% to $74.3 billion.
“2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business,” said chairman and CEO Alex Gorsky. “I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world.”
Positive contributors to operational results were sales of products that included Aveeno and Neutrogena skin care as well as Listerine oral care, the firm noted.
Breaking down the numbers, worldwide baby care reported sales in the fourth quarter fell 10.4% and oral care sales worldwide fell 1.0%. Skin care sales in Q4 were down too, falling 1.4% as US sales rose 9.0% and international sales dropped 9.9%.
For the year, worldwide baby care sales fell 2.4%, skin care sales were up 1.5% and oral care sales posted a 1.5% gain.
“2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business,” said chairman and CEO Alex Gorsky. “I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world.”
Positive contributors to operational results were sales of products that included Aveeno and Neutrogena skin care as well as Listerine oral care, the firm noted.
Breaking down the numbers, worldwide baby care reported sales in the fourth quarter fell 10.4% and oral care sales worldwide fell 1.0%. Skin care sales in Q4 were down too, falling 1.4% as US sales rose 9.0% and international sales dropped 9.9%.
For the year, worldwide baby care sales fell 2.4%, skin care sales were up 1.5% and oral care sales posted a 1.5% gain.